cs / en
Logo

Project information

Primary objectives of the project

  • collection and analysis of detailed real-life data about diagnostics and treatment of CML patients in large hemato-oncological centers in the Czech Republic
  • comparison of analytical results with international studies

Expert guarantor

  • Prof. Jiří Mayer, MD, PhD

Coordinator

  • Daniela Žáčková, MD, PhD

Contributing hemato-oncological centers

1. University Hospital Brno
    (since 1 January 1991)
2. Institute of Hematology and Blood
    Transfusion, Prague
(since 1 June 1995)
3. University Hospital Hradec Kralove
    (since 1 January 2014)
4. University Hospital Ostrava
    (since 1 September 2015)
5. University Hospital Olomouc
    (since 13 May 2019)
6. General University Hospital in Prague
    (since 13 May 2019)
7. University Hospital Plzen (since 13 May 2019)
8. University Hospital Kralovske Vinohrady,
    Prague

The INFINITY project belongs to a group of projects solved in cooperation between the CELL group and the Institute of Biostatistics and Analyses Ltd that provides the technical solution of the registry and data analysis.

Originally, the INFINITY (Imatinib In First Line CML Treatment) project has been established as a data set of patients with chronic myeloid leukaemia (CML) in the chronic phase who were treated by the first line imatinib (the so-called INFINITY I). Over time, the project was extended to incorporate other groups of patients. Specifically, the INFINITY II consisted of CML patients in the chronic phase treated by imatinib in second or other lines and patients in the accelerated phase or the blast crisis; INFINITY III comprised patients in the chronic phase treated by second generation tyrosine kinase inhibitors (TKI) – dasatinib and nilotinib. The three data sets were then merged to the centralized database INFINITY which currently includes all CML patients regardless of the type of therapy (i.e. including patients treated by other than TKI therapy).

The database INFINITY contains comprehensive real-life data about CML patients’ characteristics, their survival, TKI efficacy and tolerance. The database enables treatment event monitoring and composite endpoints analyses, which can reveal particular therapy status in a detailed and realistic manner.

Folber F., Koriťáková E. Portál české leukemické skupiny [online]. 2016 [cit. 2020-8-15]. Dostupné z: http://www.leukemia-cell.org.

2020 CELL - the Czech leukemia study group for life | site map